MX2019004096A - Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. - Google Patents

Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.

Info

Publication number
MX2019004096A
MX2019004096A MX2019004096A MX2019004096A MX2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A
Authority
MX
Mexico
Prior art keywords
leukotriene
neuroinflammation
safe
effective amount
receptor antagonist
Prior art date
Application number
MX2019004096A
Other languages
English (en)
Inventor
G Zerbe Horst
Paiement Nadine
Obeid Rodolphe
W Conway Justin
Aigner Ludwig
Original Assignee
Intelgenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelgenx Corp filed Critical Intelgenx Corp
Publication of MX2019004096A publication Critical patent/MX2019004096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un dispositivo y método para tratar una enfermedad o condición neurodegenerativa asociada con neuroinflamacion inducida por un leucotrieno; el dispositivo es una forma de dosificación unitaria de película que tiene una capa de película y una cantidad segura y efectiva de un inhibidor de la síntesis de leucotrienos o antagonista del receptor de leucotrienos; el dispositivo esta configurado y formulado para lograr el suministro transmucoso y/o enteral del inhibidor de la síntesis de leucotrienos o antagonista del receptor de leucotrienos; el método incluye suministrar por vía transmucosa y/o enteral a un animal en necesidad de tratamiento, una cantidad segura y efectiva de un bloqueador de leucotrienos capaz de cruzar la barrera hemoencefalica.
MX2019004096A 2016-10-20 2017-10-17 Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. MX2019004096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/299,054 US9949934B1 (en) 2016-10-20 2016-10-20 Device and method of treating conditions associated with neuroinflammation
PCT/CA2017/051231 WO2018072015A1 (en) 2016-10-20 2017-10-17 Device and method of treating conditions associated with neuroinflammation

Publications (1)

Publication Number Publication Date
MX2019004096A true MX2019004096A (es) 2019-09-26

Family

ID=61952387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004096A MX2019004096A (es) 2016-10-20 2017-10-17 Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.

Country Status (10)

Country Link
US (3) US9949934B1 (es)
EP (1) EP3528796B1 (es)
JP (1) JP2019531310A (es)
KR (1) KR20190071692A (es)
CN (1) CN109843273A (es)
AU (1) AU2017344764A1 (es)
BR (1) BR112019007321A2 (es)
CA (2) CA2998218C (es)
MX (1) MX2019004096A (es)
WO (1) WO2018072015A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3562486T3 (da) 2016-12-31 2024-06-10 Bioxcel Therapeutics Inc Anvendelse af sublingual dexmedetomidin til behandling af agitation
CN112888431B (zh) 2018-06-27 2022-06-03 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2020051709A1 (en) * 2018-09-14 2020-03-19 Intelgenx Corp. Method of treatment and device for the improved bio availability of montelukast, a leukotriene receptor antagonist
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US8575194B1 (en) 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
US9149472B2 (en) 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
KR101077468B1 (ko) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR20130074766A (ko) * 2011-12-26 2013-07-04 에스케이케미칼주식회사 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
US20150322049A1 (en) * 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
EP3102209B1 (en) 2014-02-04 2021-04-07 Bioscience Pharma Partners, LLC Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
CN104784157B (zh) * 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
US20170258710A1 (en) * 2016-03-11 2017-09-14 Intelgenx Corp. Montelukast transmucosal film

Also Published As

Publication number Publication date
CA2998218C (en) 2021-06-15
BR112019007321A2 (pt) 2019-07-02
JP2019531310A (ja) 2019-10-31
KR20190071692A (ko) 2019-06-24
EP3528796A1 (en) 2019-08-28
US20180228738A1 (en) 2018-08-16
EP3528796B1 (en) 2024-02-07
US20180110738A1 (en) 2018-04-26
WO2018072015A1 (en) 2018-04-26
EP3528796A4 (en) 2020-04-29
CN109843273A (zh) 2019-06-04
CA3122192A1 (en) 2018-04-20
CA2998218A1 (en) 2018-04-20
US9949934B1 (en) 2018-04-24
AU2017344764A1 (en) 2019-05-02
US20190290595A1 (en) 2019-09-26
US10722476B2 (en) 2020-07-28

Similar Documents

Publication Publication Date Title
MX2019004096A (es) Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.
GB2538682A (en) Nasal drug products and methods of their use
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
MX2019010573A (es) Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno.
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
PH12016502353A1 (en) Pharmaceutical composition
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
EA201690874A1 (ru) Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
CY1118532T1 (el) Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.